Adding targeted therapy to chemotherapy in Phase III trial is safe, results in 66% complete remission rate A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid leukemia (AML), according to the Phase III VIALE-A trial led by The University of Texas MD Anderson Cancer Center. The results were presented in the virtual 25th European Hematology Association (EHA) Annual Congress and were published today in the New England Journal of Medicine. The […]
Courtney DiNardo
Combination therapy well-tolerated and highly effective for patients with IDH1-mutated acute myeloid leukemia (AML)
Findings suggest AML treatments may be tailored to individual molecular profiles HOUSTON – A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a Phase Ib/II trial led by researchers at The University of Texas MD Anderson Cancer Center. The results of this trial may support a novel course of action for patients with AML harboring an IDH1 […]